PTN
18-6 is a pretty positive ADCOM vote. And the data is very compelling as well:
In three 24-week randomized Phase 3, six-month, double-blind, placebo-controlled, parallel-group North American studies of premenopausal women with a mean age of 36 years, ADDYI consistently demonstrated a highly statistically significant difference over placebo on three key endpoints, including increase in sexual desire, decrease in distress from the loss of sexual desire and increase in the frequency of satisfying sex.
I plan to hold through the FDA ruling....unless PTN hits 1.40 before the decision.
